Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $20.00 price target on the stock. Poseida Therapeutics Price Performance Poseida Therapeutics stock opened at $2.97 on Wednesday. Poseida Therapeutics has a one […]

Related Keywords

, Poseida Therapeutics Inc , Tower Research Capital , Allspring Global Investments Holdings , Keystone Financial Group , Dynamic Technology Lab Private Ltd , Poseida Therapeutics , Get Free Report , Capital Management , Technology Lab Private Ltd , Research Capital , Global Investments Holdings , Heme Malignancies , Poseida Therapeutics Daily ,